MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41467-026-77415-1

Медицинская библиотека · Nature communications · 2026

Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial.

Shaverdian Narek, Offin Michael, Toumbacaris Nicolas, Lee Jasme, Charalambous Karmelina, Gelblum Daphna Y, Santini Fernando C, Shepherd Annemarie F, Gewanter Richard, Mueller Boris, Shin Jacob Y, Wu Abraham J, Simone Charles B, Rimner Andreas, Lee Nancy Y, Ginsberg Michelle S, Yu Helena, Daly Bobby, Kris Mark G, Preeshagul Isabel, Paik Paul, Eng Juliana, Iqbal Afsheen, Ng Kenneth, Berger Michael, Shah Ronak, Shen Ronglai, Wong Phillip, Zhang Zhigang, Gomez Daniel R, Chaft Jamie E

СтатьяКлиническое исследование II фазыКлиническое исследование I фазыПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

CHORUS (NCT04905316) was an open-label, non-randomized, single-arm phase I/II trial of the anti-IL-1beta monoclonal antibody canakinumab given with concurrent chemoradiotherapy and continued with anti-PD-L1 durvalumab consolidation in unresectable stage III non-small cell lung cancer. The primary endpoint was 24-month progression-free survival (PFS) from radiotherapy initiation; secondary endpoints included overall survival, objective response rate, and safety. Forty-one patients were enrolled, 37 received canakinumab, and 32 comprised the prespecified efficacy population. At a median follow-up of 25 months, 24-month PFS was 67% (95% confidence interval, 52-88); the lower bound of the prespecified one-sided 90% confidence interval was 56.5%, exceeding the 46% historical benchmark, and the primary endpoint was met. Twelve- and 24-month overall survival were 93% and 73%, respectively, and the confirmed objective response rate was 81%. Canakinumab-related grade 3-4 events included neutropenia (n = 5), febrile neutropenia (n = 1), lymphopenia (n = 1), lung infection (n = 1), fatigue (n = 1), and hypertension (n = 1); no canakinumab-related deaths occurred. Pneumonitis of any attribution occurred in 9 of 37 patients (24%; grade 2, n = 7; grade 3, n = 2). Peripheral immune cell profiling showed attenuated expansion of myeloid-derived suppressor cells and CTLA-4-expressing CD8 + T-cell subsets among responders. Circulating tumor DNA cleared by week 6 in 20 of 30 evaluable patients (66%). These findings support randomized evaluation of interleukin-1β blockade in this setting.

Для цитирования: Shaverdian Narek, Offin Michael, Toumbacaris Nicolas, Lee Jasme, Charalambous Karmelina, Gelblum Daphna Y, Santini Fernando C, Shepherd Annemarie F, Gewanter Richard, Mueller Boris, Shin Jacob Y, Wu Abraham J, Simone Charles B, Rimner Andreas, Lee Nancy Y, Ginsberg Michelle S, Yu Helena, Daly Bobby, Kris Mark G, Preeshagul Isabel, Paik Paul, Eng Juliana, Iqbal Afsheen, Ng Kenneth, Berger Michael, Shah Ronak, Shen Ronglai, Wong Phillip, Zhang Zhigang, Gomez Daniel R, Chaft Jamie E. Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial.. Nature communications. 2026. DOI: 10.1038/s41467-026-77415-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.